Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Supernus Pharmaceuticals, Inc. (SUPN)
USD47.18
+0.52 (+1.11%)
US NASDAQ Healthcare Drug Manufacturers - Specialty & Generic
Address
9715 Key West Avenue 20850
Rockville, MD, US
Rockville, MD, US
CEO
Jack A. Khattar
Website
supernus.com
IPO
2012-05-01
CIK 1356576 ISIN US8684591089
Also trades on
London Stock Exchange · 0LB2.L (USD)
NASDAQ Global Market · SUPN (USD)
Description
Supernus Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for central nervous system (CNS) disorders within the United States. Its portfolio of marketed products includes Trokendi XR, an extended-release topiramate formulation prescribed for both epilepsy management and migraine prevention. Another key product is Oxtellar XR, an extended-release oxcarbazepine designed for the standalone treatment of partial-onset epileptic seizures in patients aged 6 to 17 and adults. The company also offers Qelbree, a selective norepinephrine reuptake inhibitor approved for attention-deficit hyperactivity disorder (ADHD) in children and adolescents aged 6 to 17. For advanced Parkinson's Disease (PD) patients, APOKYN offers acute, intermittent relief during "off" episodes of hypomobility, and XADAGO serves as an adjunctive treatment with levodopa/carbidopa for those experiencing similar off periods. Other offerings include GOCOVRI, which targets dyskinesia in PD patients, and Osmolex ER, used for Parkinson's disease and drug-induced extrapyramidal reactions in adults. MYOBLOC, a Type B toxin, is indicated for cervical dystonia and sialorrhea in adults. Beyond its commercial portfolio, Supernus is actively developing several investigational therapies. These include Qelbree (SPN-812), which has successfully completed Phase III trials for ADHD. SPN-830, a late-stage drug/device combination, aims to prevent off episodes in PD patients. SPN-817 is a novel compound in Phase I trials for severe epilepsy. SPN-820 is undergoing Phase II trials for resistant depression, and SPN-443 and SPN-446 are in earlier, preclinical stages for various CNS indications. Products are distributed through a network of pharmaceutical wholesalers, specialty pharmacies, and authorized distributors. Established in 2005, Supernus Pharmaceuticals is headquartered in Rockville, Maryland.
News Sentiment (7d)
Based on only 1 article — low confidence
- Strength Seen in Supernus (SUPN): Can Its 5.2% Jump Turn into More Strength? Zacks Investment Research
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD47.18
+0.52 (+1.11%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
690.8K
Beta
0.54
Float Shares
54.45M
Free Float %
94.6%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.35% | -3.68% | +1.16% | -0.61% | +13.70% | +1.67% | +56.54% | +45.45% | +69.39% | +192.42% | +840.97% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (14 ratings, all time)
Buy
Price Targets & DCF
Current price
47.18
Low
55.00
+16.6%
Consensus
60.00
+27.2%
Median
60.00
+27.2%
High
65.00
+37.8%
DCF (Unlevered)
119.05
+152.3%
DCF (Levered)
94.72
+100.8%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
83% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 4 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | 1 |
65.00
+37.8%
|
| Last Year | 6 |
55.00
+16.6%
|
| All Time | 10 |
48.50
+2.8%
|
Quality scores
Altman Z-Score
5.22
Safe zone
Piotroski F-Score
3 / 9
Average
MOAT Score
4 / 10
Developing
Composite Rating
B-
Overall Score
2 / 5
Medium
DCF Score
5 / 5
High
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+8.6% ★ Q1'26: +38.6% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-151.5% Q1'26: +81.0% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-3.3% Q1'26: +32.0% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%-6.8% Q1'26: -3.6% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%-6.2% Q1'26: -2.4% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+0.9% Q1'26: +3.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.96× ★ Q1'26: 0.55× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 4 Rev. Ana. 2 EPS Ana. |
Dec 2027 4 Rev. Ana. 2 EPS Ana. |
Dec 2028 5 Rev. Ana. 1 EPS Ana. |
Dec 2029 2 Rev. Ana. 1 EPS Ana. |
Dec 2030 2 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
144.43M
est: 144.60M (-0.1%)
|
215.00M
est: 209.53M (+2.6%)
|
302.24M
est: 300.71M (+0.5%)
|
408.90M
est: 398.42M (+2.6%)
|
392.76M
est: 399.28M (-1.6%)
|
520.40M
est: 523.01M (-0.5%)
|
579.78M
est: 579.80M (0.0%)
|
667.24M
est: 680.28M (-1.9%)
|
607.52M
est: 630.16M (-3.6%)
|
661.82M
est: 642.90M (+2.9%)
|
718.95M
est: 702.52M (+2.3%)
|
864.38M
859.28M – 869.47M
+23.0% YoY
|
1.02B
988.41M – 1.04B
+18.2% YoY
|
1.17B
1.15B – 1.19B
+14.5% YoY
|
1.30B
1.28B – 1.33B
+11.4% YoY
|
1.36B
1.34B – 1.39B
+4.7% YoY
|
| EBITDA |
21.77M
est: 36.87M (-41.0%)
|
56.62M
est: 53.42M (+6.0%)
|
107.67M
est: 79.56M (+35.3%)
|
151.51M
est: 115.55M (+31.1%)
|
180.42M
est: 186.25M (-3.1%)
|
210.54M
est: 131.44M (+60.2%)
|
129.19M
est: 139.89M (-7.6%)
|
153.36M
est: 153.88M (-0.3%)
|
90.04M
est: 117.14M (-23.1%)
|
178.28M
est: 119.51M (+49.2%)
|
42.53M
est: 130.59M (-67.4%)
|
160.68M
159.73M – 161.62M
+23.0% YoY
|
189.94M
183.73M – 193.62M
+18.2% YoY
|
217.55M
213.32M – 221.24M
+14.5% YoY
|
242.39M
237.68M – 246.51M
+11.4% YoY
|
253.71M
248.78M – 258.02M
+4.7% YoY
|
| EBIT |
20.84M
est: 22.97M (-9.3%)
|
54.22M
est: 33.29M (+62.9%)
|
99.54M
est: 71.13M (+39.9%)
|
144.44M
est: 100.70M (+43.4%)
|
170.19M
est: 156.01M (+9.1%)
|
192.40M
est: 108.58M (+77.2%)
|
96.60M
est: 105.17M (-8.2%)
|
67.81M
est: 115.69M (-41.4%)
|
5.18M
est: 44.93M (-88.5%)
|
97.87M
est: 45.83M (+113.5%)
|
-49.03M
est: 50.08M (-197.9%)
|
61.62M
61.26M – 61.99M
+23.0% YoY
|
72.85M
70.47M – 74.26M
+18.2% YoY
|
83.43M
81.81M – 84.85M
+14.5% YoY
|
92.96M
91.16M – 94.54M
+11.4% YoY
|
97.30M
95.41M – 98.96M
+4.7% YoY
|
| Net Income |
14.02M
est: 11.59M (+20.9%)
|
91.22M
est: 48.87M (+86.7%)
|
57.28M
est: 43.62M (+31.3%)
|
110.99M
est: 76.56M (+45.0%)
|
113.06M
est: 118.22M (-4.4%)
|
126.95M
est: 79.12M (+60.5%)
|
53.42M
est: 68.33M (-21.8%)
|
60.71M
est: 43.35M (+40.1%)
|
1.32M
est: 5.39M (-75.6%)
|
73.87M
est: 163.33M (-54.8%)
|
-38.55M
est: 174.53M (-122.1%)
|
139.81M
129.82M – 149.80M
-19.9% YoY
|
222.28M
204.69M – 239.87M
+59.0% YoY
|
303.23M
296.04M – 310.42M
+36.4% YoY
|
388.38M
378.58M – 396.97M
+28.1% YoY
|
394.31M
384.36M – 403.03M
+1.5% YoY
|
| SGA |
89.20M
est: 73.39M (+21.5%)
|
106.01M
est: 106.34M (-0.3%)
|
137.91M
est: 107.03M (+28.8%)
|
159.89M
est: 110.97M (+44.1%)
|
158.43M
est: 170.51M (-7.1%)
|
200.68M
est: 129.83M (+54.6%)
|
304.76M
est: 235.26M (+29.5%)
|
377.22M
est: 258.79M (+45.8%)
|
336.36M
est: 356.34M (-5.6%)
|
335.78M
est: 363.55M (-7.6%)
|
485.56M
est: 397.26M (+22.2%)
|
488.79M
485.91M – 491.67M
+23.0% YoY
|
577.80M
558.92M – 589.02M
+18.2% YoY
|
661.79M
648.94M – 673.04M
+14.5% YoY
|
737.37M
723.05M – 749.91M
+11.4% YoY
|
771.79M
756.80M – 784.91M
+4.7% YoY
|
| EPS |
0.29
est: 0.21 (+40.0%)
|
1.84
est: 0.87 (+110.7%)
|
1.13
est: 1.08 (+4.4%)
|
2.13
est: 1.88 (+13.1%)
|
2.16
est: 2.12 (+1.9%)
|
2.41
est: 2.47 (-2.3%)
|
1.01
est: 1.39 (-27.5%)
|
1.13
est: 2.15 (-47.5%)
|
0.02
est: 0.10 (-74.8%)
|
1.34
est: 2.87 (-53.4%)
|
-0.68
est: 3.10 (-122.0%)
|
2.48
2.30 – 2.65
-20.0% YoY
|
3.94
3.63 – 4.25
+59.0% YoY
|
5.38
5.24 – 5.50
+36.6% YoY
|
6.88
6.71 – 7.03
+27.9% YoY
|
6.99
6.81 – 7.14
+1.5% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-08 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-07 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-06 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-05 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-04 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-01 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-30 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-29 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-28 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-27 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-24 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-23 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-22 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-21 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-20 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-17 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-16 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
85.46M
OE per share TTM
1.48
Owner's Yield
2.93%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
3.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
89
Total invested
213.06M
Insider transactions (90d)
0
Beneficial owners (>5%)
22
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | (1) BlackRock, Inc. | 8.45M | 15.90% | 8.32M | — | — | 8.32M | HC | Delaware | 2022-01-27 | ↗ |
| 2 | The Vanguard Group - 23-1945930 | 5.51M | 10.37% | — | 41.6K | 5.43M | 88.1K | IA | Pennsylvania For | 2022-02-10 | ↗ |
| 3 | Armistice Capital, LLC | 4.14M | 7.80% | — | 4.14M | — | 4.14M | IA, OO | — | 2022-02-15 | ↗ |
| 4 | Steven Boyd | 4.14M | 7.80% | — | 4.14M | — | 4.14M | HC, IN | Delaware | 2022-02-15 | ↗ |
| 5 | Scott D. Sandell | 4.12M | 8.40% | 82.8K | 4.03M | 82.8K | 10.00 | IN | United States citizen | 2015-11-24 | ↗ |
| 6 | Michael James Barrett | 3.98M | 8.10% | 164.0K | 3.82M | 164.0K | 10.00 | IN | United States citizen | 2015-11-24 | ↗ |
| 7 | Krishna S. Kolluri | 3.84M | 7.90% | 20.5K | 3.82M | 20.5K | 10.00 | IN | United States citizen | 2015-11-24 | ↗ |
| 8 | NEA 11 GP, LLC | 3.82M | 7.80% | — | 3.82M | — | 10.00 | OO | Delaware | 2015-11-24 | ↗ |
| 9 | NEA Partners 11, Limited Partnership | 3.82M | 7.80% | — | 3.82M | — | 10.00 | PN | Delaware | 2015-11-24 | ↗ |
| 10 | 30-0447847 | 2.88M | 5.20% | 2.79M | — | 2.88M | — | IA | Delaware | 2024-10-31 | ↗ |
| 11 | Jack A. Khattar | 2.75M | 5.13% | 2.75M | — | 2.75M | 10.00 | IN | United States of America | 2019-04-25 | ↗ |
| 12 | Macquarie Group Limited | 2.74M | 5.01% | — | — | — | — | HC | Sydney, New South Wales Australia | 2024-02-14 | ↗ |
| 13 | Macquarie Investment Management Business Trust | 2.74M | 5.01% | 2.74M | — | 2.74M | — | IA | Sydney, New South Wales Australia | 2024-02-14 | ↗ |
| 14 | Macquarie Management Holdings Inc | 2.74M | 5.01% | 2.74M | — | 2.74M | — | HC | Sydney, New South Wales Australia | 2024-02-14 | ↗ |
| 15 | Ardsley Advisory Partners | — | 0.00% | — | — | — | — | IA, PN | Delaware | 2016-02-16 | ↗ |
| 16 | Ardsley Healthcare Fund, LP | — | 0.00% | — | — | — | — | PN | Delaware | 2016-02-16 | ↗ |
| 17 | Ardsley Partners Fund II, L.P. | — | 0.00% | — | — | — | — | PN | Delaware | 2016-02-16 | ↗ |
| 18 | Ardsley Partners I | — | 0.00% | — | — | — | — | PN | Delaware | 2016-02-16 | ↗ |
| 19 | Fund plc | — | 0.00% | — | — | — | — | PN | Delaware | 2016-02-16 | ↗ |
| 20 | Fund, L.P. | — | 0.00% | — | — | — | — | PN | Delaware | 2016-02-16 | ↗ |
| 21 | L.P. | — | 0.00% | — | — | — | — | PN | Delaware | 2016-02-16 | ↗ |
| 22 | Philip J. Hempleman | — | 0.00% | — | — | — | — | IN | Delaware | 2016-02-16 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
89
-251 vs prev Q
New positions
9
Closed positions
253
Increased
38
Reduced
31
Put/Call ratio
0.00
Calls held
671.00
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | MACQUARIE MANAGEMENT HOLDINGS, INC. | 2.31M +2.3M (+100.0%) | 114.69B +114.7B (+100.0%) | 4.09% +4.092 pp | 0.17% +0.173 pp | USD49.70 +0.0% | 1 qtrs NEW |
| 2 | BLACKROCK, INC. | 8.74M +37.5K (+0.4%) | 434.17M +18.5M (+4.4%) | 15.49% -0.036 pp | 0.01% +0.000 pp | USD31.26 +59.0% | 6 qtrs — |
| 3 | VANGUARD GROUP INC | 6.05M +3.7K (+0.1%) | 300.61M +11.7M (+4.1%) | 10.73% -0.064 pp | 0.00% +0.000 pp | USD29.85 +66.5% | 54 qtrs — |
| 4 | ARMISTICE CAPITAL, LLC | 2.76M -72.0K (-2.5%) | 137.37M +1.8M (+1.4%) | 4.90% -0.161 pp | 1.63% -0.376 pp | USD26.36 +88.5% | 25 qtrs — |
| 5 | DIMENSIONAL FUND ADVISORS LP | 2.71M -289.6K (-9.6%) | 134.80M -8.7M (-6.0%) | 4.81% -0.549 pp | 0.03% -0.003 pp | USD25.39 +95.7% | 43 qtrs — |
| 6 | MILLENNIUM MANAGEMENT LLC | 2.64M +2.3M (+662.4%) | 131.21M +114.7M (+692.8%) | 4.68% +4.063 pp | 0.06% +0.048 pp | USD49.37 +0.7% | 55 qtrs — |
| 7 | POINT72 ASSET MANAGEMENT, L.P. | 2.26M +503.3K (+28.6%) | 112.56M +28.4M (+33.7%) | 4.02% +0.872 pp | 0.13% -0.015 pp | USD44.78 +11.0% | 8 qtrs — |
| 8 | STATE STREET CORP | 2.22M +31.7K (+1.4%) | 110.30M +5.8M (+5.5%) | 3.94% +0.030 pp | 0.00% +0.000 pp | USD27.56 +80.3% | 51 qtrs — |
| 9 | RENAISSANCE TECHNOLOGIES LLC | 1.73M -8.1K (-0.5%) | 86.11M +2.9M (+3.5%) | 3.07% -0.035 pp | 0.13% +0.024 pp | USD30.58 +62.5% | 33 qtrs — |
| 10 | GEODE CAPITAL MANAGEMENT, LLC | 1.47M +62.9K (+4.5%) | 73.21M +5.8M (+8.6%) | 2.61% +0.095 pp | 0.00% +0.000 pp | USD29.11 +70.7% | 55 qtrs — |
| 11 | LOOMIS SAYLES & CO L P | 1.45M +162.9K (+12.7%) | 72.01M +10.6M (+17.2%) | 2.57% +0.274 pp | 0.09% +0.014 pp | USD31.94 +55.6% | 41 qtrs — |
| 12 | STEPHENS INVESTMENT MANAGEMENT GROUP LLC | 1.41M +61.1K (+4.5%) | 69.90M +5.6M (+8.7%) | 2.49% +0.093 pp | 0.91% +0.077 pp | USD29.84 +66.6% | 33 qtrs — |
| 13 | GW&K INVESTMENT MANAGEMENT, LLC | 1.08M +178.0 (+0.0%) | 53.71M +2.1M (+4.0%) | 1.92% -0.012 pp | 0.46% +0.008 pp | USD26.08 +90.6% | 23 qtrs — |
| 14 | MORGAN STANLEY | 1.08M +324.2K (+42.9%) | 53.65M +17.6M (+48.6%) | 1.91% +0.566 pp | 0.00% +0.001 pp | USD37.29 +33.3% | 51 qtrs — |
| 15 | D. E. SHAW & CO., INC. | 708.0K -271.6K (-27.7%) | 35.19M -11.6M (-24.8%) | 1.26% -0.493 pp | 0.02% -0.007 pp | USD37.45 +32.7% | 16 qtrs — |
| 16 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 703.6K -28.9K (-3.9%) | 34.97M -35.5K (-0.1%) | 1.25% -0.060 pp | 0.01% 0.000 pp | USD29.51 +68.4% | 55 qtrs — |
| 17 | NORTHERN TRUST CORP | 670.4K -33.1K (-4.7%) | 33.32M -303.4K (-0.9%) | 1.19% -0.067 pp | 0.00% 0.000 pp | USD24.21 +105.3% | 51 qtrs — |
| 18 | GOLDMAN SACHS GROUP INC | 660.3K -502.7K (-43.2%) | 32.82M -22.8M (-41.0%) | 1.17% -0.905 pp | 0.00% -0.003 pp | USD34.24 +45.2% | 49 qtrs — |
| 19 | ASHFORD CAPITAL MANAGEMENT INC | 612.5K +48.8K (+8.7%) | 30.44M +3.5M (+13.0%) | 1.09% +0.080 pp | 3.39% +0.391 pp | USD26.41 +88.2% | 45 qtrs — |
| 20 | SOFINNOVA INVESTMENTS, INC. | 553.1K +176.0K (+46.7%) | 27.49M +9.5M (+52.5%) | 0.98% +0.308 pp | 1.19% +0.200 pp | USD37.85 +31.3% | 4 qtrs — |
| 21 | VICTORY CAPITAL MANAGEMENT INC | 526.2K -33.6K (-6.0%) | 26.15M -601.4K (-2.2%) | 0.93% -0.066 pp | 0.01% -0.001 pp | USD26.09 +90.5% | 42 qtrs — |
| 22 | BANK OF AMERICA CORP /DE/ | 520.7K -322.1K (-38.2%) | 25.88M -14.4M (-35.7%) | 0.92% -0.581 pp | 0.00% -0.001 pp | USD38.50 +29.1% | 52 qtrs — |
| 23 | PICTET ASSET MANAGEMENT HOLDING SA | 483.4K -25.5K (-5.0%) | 24.76M +533.6K (+2.2%) | 0.86% -0.051 pp | 0.02% +0.001 pp | USD28.05 +77.2% | 10 qtrs — |
| 24 | RICE HALL JAMES & ASSOCIATES, LLC | 467.9K -8.2K (-1.7%) | 23.25M +502.0K (+2.2%) | 0.83% -0.020 pp | 1.28% +0.040 pp | USD29.04 +71.1% | 43 qtrs — |
| 25 | CITADEL ADVISORS LLC | 453.0K -964.0K (-68.0%) | 22.51M -45.2M (-66.8%) | 0.80% -1.726 pp | 0.00% -0.007 pp | USD45.60 +9.0% | 21 qtrs — |
| 26 | INVESCO LTD. | 395.8K +33.9K (+9.4%) | 19.67M +2.4M (+13.7%) | 0.70% +0.056 pp | 0.00% +0.000 pp | USD29.99 +65.7% | 43 qtrs — |
| 27 | BANK OF NEW YORK MELLON CORP | 370.8K -5.8K (-1.5%) | 18.43M +430.4K (+2.4%) | 0.66% -0.015 pp | 0.00% 0.000 pp | USD20.10 +147.3% | 54 qtrs — |
| 28 | PRINCIPAL FINANCIAL GROUP INC | 326.0K +22.6K (+7.5%) | 16.20M +1.7M (+11.8%) | 0.58% +0.037 pp | 0.01% +0.001 pp | USD26.73 +85.9% | 43 qtrs — |
| 29 | KRENSAVAGE ASSET MANAGEMENT, LLC | 313.5K -50.0K (-13.8%) | 15.58M -1.8M (-10.3%) | 0.56% -0.093 pp | 5.50% -1.898 pp | USD32.64 +52.3% | 4 qtrs — |
| 30 | QUBE RESEARCH & TECHNOLOGIES LTD | 311.8K +187.7K (+151.2%) | 15.50M +9.6M (+161.3%) | 0.55% +0.331 pp | 0.02% +0.010 pp | USD41.99 +18.4% | 14 qtrs — |
| 31 | ACADIAN ASSET MANAGEMENT LLC | 306.7K +82.5K (+36.8%) | 15.23M +4.5M (+42.3%) | 0.54% +0.144 pp | 0.03% +0.006 pp | USD47.86 +3.8% | 6 qtrs — |
| 32 | SYSTEMATIC FINANCIAL MANAGEMENT LP | 304.2K +12.0K (+4.1%) | 15.12M +1.2M (+8.3%) | 0.54% +0.018 pp | 0.36% +0.017 pp | USD36.22 +37.2% | 6 qtrs — |
| 33 | METLIFE INVESTMENT MANAGEMENT, LLC | 303.7K +271.5K (+842.4%) | 15.09M +13.6M (+880.1%) | 0.54% +0.481 pp | 0.07% +0.066 pp | USD48.26 +3.0% | 33 qtrs — |
| 34 | ABRDN PLC | 271.6K +271.6K (+100.0%) | 13.50M +13.5M (+100.0%) | 0.48% +0.482 pp | 0.02% +0.021 pp | USD49.70 +0.0% | 1 qtrs NEW |
| 35 | CATALIO CAPITAL MANAGEMENT, LP | 257.5K -29.6K (-10.3%) | 12.80M -924.0K (-6.7%) | 0.46% -0.056 pp | 2.26% -0.275 pp | USD47.79 +4.0% | 2 qtrs — |
| 36 | JPMORGAN CHASE & CO | 251.8K +80.5K (+47.0%) | 12.51M +4.3M (+52.9%) | 0.45% +0.141 pp | 0.00% +0.000 pp | USD37.67 +31.9% | 41 qtrs — |
| 37 | GLENMEDE TRUST CO NA | 239.2K +239.2K (+100.0%) | 11.89M +11.9M (+100.0%) | 0.42% +0.424 pp | 0.06% +0.056 pp | USD49.70 +0.0% | 1 qtrs NEW |
| 38 | ARISTOTLE CAPITAL BOSTON, LLC | 234.5K -70.8K (-23.2%) | 11.65M -2.9M (-20.1%) | 0.42% -0.129 pp | 0.64% -0.112 pp | USD27.20 +82.7% | 27 qtrs — |
| 39 | EXODUSPOINT CAPITAL MANAGEMENT, LP | 229.1K +229.1K (+100.0%) | 11.39M +11.4M (+100.0%) | 0.41% +0.406 pp | 0.09% +0.089 pp | USD49.70 +0.0% | 1 qtrs NEW |
| 40 | PUBLIC SECTOR PENSION INVESTMENT BOARD | 198.4K -20.3K (-9.3%) | 9.86M -590.1K (-5.6%) | 0.35% -0.039 pp | 0.03% -0.005 pp | USD31.25 +59.0% | 43 qtrs — |
| 41 | ROYCE & ASSOCIATES LP | 197.7K +157.0K (+385.1%) | 9.83M +7.9M (+404.5%) | 0.35% +0.278 pp | 0.10% +0.080 pp | USD47.01 +5.7% | 5 qtrs — |
| 42 | FREESTONE GROVE PARTNERS LP | 196.3K +196.3K (+100.0%) | 9.76M +9.8M (+100.0%) | 0.35% +0.348 pp | 0.07% +0.071 pp | USD49.70 +0.0% | 1 qtrs NEW |
| 43 | MUTUAL OF AMERICA CAPITAL MANAGEMENT LLC | 193.6K -5.7K (-2.9%) | 9.62M +97.9K (+1.0%) | 0.34% -0.012 pp | 0.10% +0.001 pp | USD20.33 +144.5% | 51 qtrs — |
| 44 | SCHRODER INVESTMENT MANAGEMENT GROUP | 189.9K +189.9K (+100.0%) | 9.48M +9.5M (+100.0%) | 0.34% +0.337 pp | 0.01% +0.007 pp | USD49.70 +0.0% | 9 qtrs — |
| 45 | THIRD AVENUE MANAGEMENT LLC | 189.5K +— (+0.0%) | 9.42M +314.6K (+3.5%) | 0.34% -0.002 pp | 1.71% +0.003 pp | USD28.60 +73.8% | 15 qtrs — |
| 46 | ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 183.7K -42.7K (-18.9%) | 9.13M -1.7M (-15.6%) | 0.33% -0.078 pp | 0.01% -0.002 pp | USD33.18 +49.8% | 6 qtrs — |
| 47 | AMERIPRISE FINANCIAL INC | 181.0K -2.3K (-1.2%) | 9.00M +236.4K (+2.7%) | 0.32% -0.006 pp | 0.00% +0.000 pp | USD24.45 +103.3% | 51 qtrs — |
| 48 | AMERICAN CENTURY COMPANIES INC | 165.2K -344.1K (-67.6%) | 8.21M -16.1M (-66.3%) | 0.29% -0.616 pp | 0.00% -0.008 pp | USD29.96 +65.9% | 24 qtrs — |
| 49 | RHUMBLINE ADVISERS | 164.4K -5.5K (-3.2%) | 8.17M +53.4K (+0.7%) | 0.29% -0.012 pp | 0.01% +0.000 pp | USD28.10 +76.9% | 51 qtrs — |
| 50 | SEI INVESTMENTS CO | 154.6K +1.2K (+0.8%) | 7.68M +351.3K (+4.8%) | 0.27% +0.000 pp | 0.01% 0.000 pp | USD29.75 +67.1% | 43 qtrs — |
| 51 | LEGAL & GENERAL GROUP PLC | 145.2K -6.5K (-4.3%) | 7.22M -34.1K (-0.5%) | 0.26% -0.013 pp | 0.00% +0.000 pp | USD30.42 +63.4% | 46 qtrs — |
| 52 | SUSQUEHANNA PORTFOLIO STRATEGIES, LLC | 142.2K -13.4K (-8.6%) | 7.07M -368.2K (-5.0%) | 0.25% -0.026 pp | 0.11% -0.009 pp | USD42.84 +16.0% | 3 qtrs — |
| 53 | TEACHER RETIREMENT SYSTEM OF TEXAS | 130.9K +18.3K (+16.2%) | 6.51M +1.1M (+20.9%) | 0.23% +0.031 pp | 0.02% +0.001 pp | USD46.50 +6.9% | 19 qtrs — |
| 54 | AQR CAPITAL MANAGEMENT LLC | 126.2K -10.2K (-7.5%) | 6.27M -246.2K (-3.8%) | 0.22% -0.020 pp | 0.00% -0.001 pp | USD31.55 +57.5% | 15 qtrs — |
| 55 | JACOBS LEVY EQUITY MANAGEMENT, INC | 126.2K +87.0K (+222.2%) | 6.27M +4.4M (+235.1%) | 0.22% +0.154 pp | 0.02% +0.017 pp | USD49.11 +1.2% | 2 qtrs — |
| 56 | FMR LLC | 124.3K +23.9K (+23.8%) | 6.18M +1.4M (+28.7%) | 0.22% +0.041 pp | 0.00% +0.000 pp | USD39.71 +25.2% | 43 qtrs — |
| 57 | JAIN GLOBAL LLC | 123.3K +123.3K (+100.0%) | 6.13M +6.1M (+100.0%) | 0.22% +0.219 pp | 0.03% +0.030 pp | USD49.70 +0.0% | 1 qtrs NEW |
| 58 | TWO SIGMA INVESTMENTS, LP | 120.7K -137.3K (-53.2%) | 6.00M -6.3M (-51.4%) | 0.21% -0.247 pp | 0.01% -0.010 pp | USD44.27 +12.3% | 16 qtrs — |
| 59 | NORGES BANK | 120.4K +120.4K (+100.0%) | 5.98M +6.0M (+100.0%) | 0.21% +0.214 pp | 0.00% +0.001 pp | USD49.70 +0.0% | 1 qtrs NEW |
| 60 | DEUTSCHE BANK AG\ | 113.3K +965.0 (+0.9%) | 5.63M +262.6K (+4.9%) | 0.20% +0.000 pp | 0.00% +0.000 pp | USD42.85 +16.0% | 50 qtrs — |
| 61 | BREVAN HOWARD CAPITAL MANAGEMENT LP | 113.2K +101.7K (+888.9%) | 5.63M +5.1M (+928.4%) | 0.20% +0.180 pp | 0.06% +0.059 pp | USD48.04 +3.5% | 5 qtrs — |
| 62 | CAXTON ASSOCIATES LLP | 113.1K +89.7K (+383.7%) | 5.62M +4.5M (+403.0%) | 0.20% +0.159 pp | 0.11% +0.084 pp | USD49.31 +0.8% | 2 qtrs — |
| 63 | NUVEEN, LLC | 110.8K -175.3K (-61.3%) | 5.51M -8.2M (-59.7%) | 0.20% -0.314 pp | 0.00% -0.002 pp | USD41.96 +18.4% | 4 qtrs — |
| 64 | SWISS NATIONAL BANK | 110.6K +2.1K (+1.9%) | 5.50M +311.6K (+6.0%) | 0.20% +0.002 pp | 0.00% +0.000 pp | USD26.73 +85.9% | 43 qtrs — |
| 65 | BARCLAYS PLC | 109.5K +669.0 (+0.6%) | 5.44M +2.0M (+60.4%) | 0.19% 0.000 pp | 0.00% +0.000 pp | USD31.17 +59.4% | 51 qtrs — |
| 66 | AXIOM INVESTORS LLC /DE | 106.2K +1.5K (+1.5%) | 5.28M +276.8K (+5.5%) | 0.19% +0.002 pp | 0.05% +0.010 pp | USD39.73 +25.1% | 13 qtrs — |
| 67 | UBS ASSET MANAGEMENT AMERICAS INC | 101.0K +8.0 (+0.0%) | 5.02M +193.4K (+4.0%) | 0.18% -0.001 pp | 0.00% +0.000 pp | USD31.69 +56.8% | 43 qtrs — |
| 68 | EDGESTREAM PARTNERS, L.P. | 100.0K +100.0K (+100.0%) | 4.97M +5.0M (+100.0%) | 0.18% +0.177 pp | 0.14% +0.140 pp | USD49.70 +0.0% | 1 qtrs NEW |
| 69 | SQUAREPOINT OPS LLC | 92.4K +25.2K (+37.4%) | 4.59M +1.4M (+42.9%) | 0.16% +0.044 pp | 0.00% +0.002 pp | USD36.82 +35.0% | 6 qtrs — |
| 70 | FRANKLIN RESOURCES INC | 91.0K -4.4K (-4.6%) | 4.52M -34.8K (-0.8%) | 0.16% -0.009 pp | 0.00% +0.000 pp | USD40.90 +21.5% | 12 qtrs — |
| 71 | QUANTEDGE CAPITAL PTE LTD | 89.6K -31.5K (-26.0%) | 4.45M -1.3M (-23.1%) | 0.16% -0.057 pp | 2.12% -1.045 pp | USD47.79 +4.0% | 2 qtrs — |
| 72 | RAYMOND JAMES FINANCIAL INC | 89.0K +89.0K (+100.0%) | 4.42M +4.4M (+100.0%) | 0.16% +0.158 pp | 0.00% +0.001 pp | USD49.70 +0.0% | 5 qtrs — |
| 73 | RUSSELL INVESTMENTS GROUP, LTD. | 88.1K +25.6K (+40.9%) | 4.38M +1.4M (+46.6%) | 0.16% +0.045 pp | 0.00% +0.001 pp | USD38.85 +27.9% | 37 qtrs — |
| 74 | BRUCE & CO., INC. | 82.1K +— (+0.0%) | 4.08M +156.8K (+4.0%) | 0.15% -0.001 pp | 1.27% +0.050 pp | USD27.67 +79.6% | 47 qtrs — |
| 75 | PHOCAS FINANCIAL CORP. | 81.3K +81.3K (+100.0%) | 4.04M +4.0M (+100.0%) | 0.14% +0.144 pp | 0.53% +0.526 pp | USD49.70 +0.0% | 1 qtrs NEW |
| 76 | HENNION & WALSH ASSET MANAGEMENT, INC. | 80.7K -21.1K (-20.7%) | 4.01M -853.8K (-17.6%) | 0.14% -0.039 pp | 0.14% -0.038 pp | USD33.52 +48.3% | 9 qtrs — |
| 77 | UNIVERSAL- BETEILIGUNGS- UND SERVICEGESELLSCHAFT MBH | 80.4K -29.4K (-26.8%) | 4.00M -1.3M (-23.8%) | 0.14% -0.053 pp | 0.01% -0.002 pp | USD35.85 +38.6% | 4 qtrs — |
| 78 | NEW YORK STATE TEACHERS RETIREMENT SYSTEM | 80.0K -5.4K (-6.4%) | 3.97M -106.0K (-2.6%) | 0.14% -0.011 pp | 0.01% 0.000 pp | USD21.02 +136.4% | 43 qtrs — |
| 79 | WEDGE CAPITAL MANAGEMENT L L P/NC | 78.1K +8.5K (+12.2%) | 3.88M +556.0K (+16.7%) | 0.14% +0.014 pp | 0.07% +0.013 pp | USD36.69 +35.5% | 5 qtrs — |
| 80 | BNP PARIBAS ARBITRAGE, SNC | 77.6K -338.1K (-81.3%) | 3.86M -16.0M (-80.6%) | 0.14% -0.604 pp | 0.00% -0.009 pp | USD37.94 +31.0% | 49 qtrs — |
| 81 | PDT PARTNERS, LLC | 76.7K -11.6K (-13.1%) | 3.81M -407.9K (-9.7%) | 0.14% -0.022 pp | 0.25% -0.019 pp | USD32.03 +55.2% | 8 qtrs — |
| 82 | S&T BANK/PA | 75.1K -13.8K (-15.5%) | 3.73M -515.6K (-12.1%) | 0.13% -0.026 pp | 1.18% -0.014 pp | USD31.08 +59.9% | 28 qtrs — |
| 83 | PRUDENTIAL FINANCIAL INC | 73.2K -34.4K (-31.9%) | 3.64M -1.5M (-29.2%) | 0.13% -0.062 pp | 0.00% -0.002 pp | USD30.61 +62.4% | 44 qtrs — |
| 84 | SIT INVESTMENT ASSOCIATES INC | 65.2K +250.0 (+0.4%) | 3.24M +136.0K (+4.4%) | 0.12% 0.000 pp | 0.06% +0.001 pp | USD32.12 +54.7% | 9 qtrs — |
| 85 | STATE OF WISCONSIN INVESTMENT BOARD | 64.6K +29.8K (+85.5%) | 3.21M +1.5M (+93.0%) | 0.11% +0.052 pp | 0.01% +0.003 pp | USD39.97 +24.3% | 35 qtrs — |
| 86 | BRIDGE CITY CAPITAL, LLC | 63.8K -9.0K (-12.4%) | 3.17M -309.0K (-8.9%) | 0.11% -0.017 pp | 0.93% +0.003 pp | USD30.80 +61.4% | 35 qtrs — |
| 87 | INTECH INVESTMENT MANAGEMENT LLC | 61.5K +25.8K (+72.3%) | 3.06M +1.4M (+79.2%) | 0.11% +0.045 pp | 0.03% +0.012 pp | USD39.46 +26.0% | 7 qtrs — |
| 88 | WELLS FARGO & COMPANY/MN | 61.1K +19.3K (+46.2%) | 3.04M +1.0M (+52.1%) | 0.11% +0.034 pp | 0.00% +0.000 pp | USD36.28 +37.0% | 47 qtrs — |
| 89 | STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | 59.6K -5.0K (-7.8%) | 2.96M -125.5K (-4.1%) | 0.11% -0.010 pp | 0.01% 0.000 pp | USD31.51 +57.7% | 51 qtrs — |
| 90 | MARTINGALE ASSET MANAGEMENT L P | 58.3K -1.7K (-2.8%) | 2.90M +30.8K (+1.1%) | 0.10% -0.004 pp | 0.07% +0.002 pp | USD30.92 +60.7% | 23 qtrs — |
| 91 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | 58.0K -35.6K (-38.0%) | 2.88M -1.6M (-35.6%) | 0.10% -0.064 pp | 0.06% -0.035 pp | USD32.19 +54.4% | 4 qtrs — |
| 92 | CAPTION MANAGEMENT, LLC | 57.7K +57.7K (+100.0%) | 2.87M +2.9M (+100.0%) | 0.10% +0.102 pp | 0.02% +0.020 pp | USD49.70 +0.0% | 1 qtrs NEW |
| 93 | ALLIANCEBERNSTEIN L.P. | 54.1K +30.0 (+0.1%) | 2.69M +104.7K (+4.1%) | 0.10% -0.001 pp | 0.00% +0.000 pp | USD27.72 +79.3% | 54 qtrs — |
| 94 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 53.3K -68.0 (-0.1%) | 2.65M +98.6K (+3.9%) | 0.09% -0.001 pp | 0.00% +0.000 pp | USD19.45 +155.5% | 52 qtrs — |
| 95 | PRICE T ROWE ASSOCIATES INC /MD/ | 52.8K +2.9K (+5.8%) | 2.62M +238.0K (+10.0%) | 0.09% +0.005 pp | 0.00% +0.000 pp | USD33.79 +47.1% | 55 qtrs — |
| 96 | GREAT LAKES ADVISORS, LLC | 52.6K -18.6K (-26.1%) | 2.61M -789.2K (-23.2%) | 0.09% -0.034 pp | 0.02% -0.007 pp | USD36.16 +37.4% | 5 qtrs — |
| 97 | STIFEL FINANCIAL CORP | 50.4K -12.4K (-19.7%) | 2.50M -495.1K (-16.5%) | 0.09% -0.023 pp | 0.00% -0.001 pp | USD29.60 +67.9% | 48 qtrs — |
| 98 | CASTLEKEEP INVESTMENT ADVISORS LLC | 50.1K +— (+0.0%) | 2.49M +95.7K (+4.0%) | 0.09% -0.001 pp | 1.13% +0.007 pp | USD34.79 +42.9% | 3 qtrs — |
| 99 | VELA INVESTMENT MANAGEMENT, LLC | 49.9K +9.7K (+24.0%) | 2.48M +556.9K (+29.0%) | 0.09% +0.017 pp | 0.58% +0.114 pp | USD48.16 +3.2% | 2 qtrs — |
| 100 | GREAT WEST LIFE ASSURANCE CO /CAN/ | 48.2K -12.9K (-21.1%) | 2.39M -515.0K (-17.7%) | 0.09% -0.024 pp | 0.00% +0.000 pp | USD27.21 +82.7% | 42 qtrs — |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 165 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | AdvisorShares Psychedelics ETF PSIL | 3.02% | 1.34M | 1.84% |
| 2 | Invesco Pharmaceuticals ETF PJP | 2.71% | 9.71M | 0.57% |
| 3 | abrdn Focused U.S. Small Cap Active ETF AFSC | 2.45% | 245.3K | 1.09% |
| 4 | State Street SPDR S&P Pharmaceuticals ETF XPH | 1.57% | 7.38M | 0.35% |
| 5 | Invesco S&P SmallCap Health Care ETF PSCH | 1.23% | 2.01M | 0.29% |
| 6 | ETC 6 Meridian Small Cap Equity ETF SIXS | 0.91% | 970.7K | 0.52% |
| 7 | Hartford Multifactor Small Cap ETF ROSC | 0.67% | 408.6K | 0.34% |
| 8 | iShares U.S. Pharmaceuticals ETF IHE | 0.63% | 8.50M | 0.38% |
| 9 | Goldman Sachs Small Cap Equity ETF GSC | 0.57% | 1.64M | 0.80% |
| 10 | First Trust Multi-Manager Small Cap Opportunities ETF MMSC | 0.49% | 262.6K | 0.95% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.81
Neutral
Ratio by volume
1.62
Bullish
Buys
62
Sells
77
Shares acquired
753.6K
Shares disposed
464.3K
Cash buys
—
Cash sales
17.00
Net activity
+289,304
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-18 | Bhatt Padmanabh P. | Officer | M-Exempt | D | Employee Stock Option (Right to Buy) | 7,250 | 39.40 | 285.7K | 0 | D | ↗ |
| 2026-03-17 | Bhatt Padmanabh P. | Officer | M-Exempt | A | Common Stock | 15,000 | 38.60 | 579.0K | 67,044 | D | ↗ |
| 2026-03-16 | Bhatt Padmanabh P. | Officer | M-Exempt | A | Common Stock | 5,000 | 27.94 | 139.7K | 67,044 | D | ↗ |
| 2026-03-13 | Khattar Jack A. | Director / Officer | S-Sale | D | Common Stock | 120 | 51.75 | 6.2K | 958,100 | I | ↗ |
| 2026-03-12 | Hudson Frederick M. | Director | S-Sale | D | Common Stock | 5,369 | 50.61 | 271.7K | 60,413 | D | ↗ |
| 2026-03-10 | Horich William Todd | Officer | S-Sale | D | Common Stock | 4,439 | 55.00 | 244.1K | 0 | D | ↗ |
| 2026-03-09 | Mottola Frank | Officer | S-Sale | D | Common Stock | 1,623 | 53.65 | 87.1K | 18,440 | D | ↗ |
| 2026-03-09 | Horich William Todd | Officer | S-Sale | D | Common Stock | 4,438 | 54.00 | 239.7K | 4,439 | D | ↗ |
| 2026-03-06 | Mottola Frank | Officer | M-Exempt | D | Performance Share Unit | 3,750 | 0.00 | — | 0 | D | ↗ |
| 2026-03-06 | Khattar Jack A. | Director / Officer | M-Exempt | A | Common Stock | 38,640 | 0.00 | — | 1,245,218 | D | ↗ |
| 2026-03-06 | Horich William Todd | Officer | M-Exempt | A | Common Stock | 1,125 | 0.00 | — | 9,398 | D | ↗ |
| 2026-03-06 | GEMAYEL GEORGES | Director | S-Sale | D | Common Stock | 8,787 | 53.00 | 465.7K | 27,277 | D | ↗ |
| 2026-03-06 | DEC TIMOTHY C | Officer | M-Exempt | D | Performance Share Unit | 3,000 | 0.00 | — | 0 | D | ↗ |
| 2026-03-05 | GEMAYEL GEORGES | Director | S-Sale | D | Common Stock | 10,000 | 53.71 | 537.1K | 28,159 | D | ↗ |
| 2026-03-01 | Horich William Todd | Officer | — | — | Restricted Stock Unit | 3,000 | 0.00 | — | 0 | D | ↗ |
| 2026-02-28 | Mottola Frank | Officer | A-Award | A | Performance Share Unit | 3,750 | 0.00 | — | 3,750 | D | ↗ |
| 2026-02-28 | Khattar Jack A. | Director / Officer | A-Award | A | Performance Share Unit | 38,640 | 0.00 | — | 38,640 | D | ↗ |
| 2026-02-28 | DEC TIMOTHY C | Officer | A-Award | A | Performance Share Unit | 3,000 | 0.00 | — | 3,000 | D | ↗ |
| 2026-02-25 | Rubin Jonathan | Officer | F-InKind | D | Common Stock | 675 | 50.69 | 34.2K | 13,341 | D | ↗ |
| 2026-02-25 | Mottola Frank | Officer | D-Return | D | Restricted Stock Unit | 1,875 | 0.00 | — | 1,875 | D | ↗ |
| 2026-02-25 | DEC TIMOTHY C | Officer | D-Return | D | Restricted Stock Unit | 2,500 | 0.00 | — | 2,500 | D | ↗ |
| 2026-02-25 | Bhatt Padmanabh P. | Officer | D-Return | D | Restricted Stock Unit | 1,250 | 0.00 | — | 1,250 | D | ↗ |
| 2026-02-24 | Rubin Jonathan | Officer | A-Award | A | Common Stock | 1,250 | 0.00 | — | 13,437 | D | ↗ |
| 2026-02-24 | NEWHALL CHARLES W III | Director | D-Return | D | Restricted Stock Unit | 4,475 | 0.00 | — | 0 | D | ↗ |
| 2026-02-24 | Mottola Frank | Officer | A-Award | A | Common Stock | 1,250 | 0.00 | — | 17,878 | D | ↗ |
| 2026-02-24 | Hudson Frederick M. | Director | A-Award | A | Common Stock | 4,475 | 0.00 | — | 65,782 | D | ↗ |
| 2026-02-24 | GEMAYEL GEORGES | Director | A-Award | A | Common Stock | 4,475 | 0.00 | — | 38,159 | D | ↗ |
| 2026-02-24 | DEC TIMOTHY C | Officer | F-InKind | D | Common Stock | 1,524 | 50.86 | 77.5K | 3,894 | D | ↗ |
| 2026-02-24 | Bhatt Padmanabh P. | Officer | D-Return | D | Restricted Stock Unit | 1,250 | 0.00 | — | 2,500 | D | ↗ |
| 2026-02-24 | Barlow Carrolee | Director | A-Award | A | Common Stock | 4,475 | 0.00 | — | 27,045 | D | ↗ |
| 2026-02-23 | GEMAYEL GEORGES | Director | M-Exempt | A | Common Stock | 15,000 | 12.98 | 194.7K | 33,684 | D | ↗ |
| 2026-02-19 | Sensenig Bethany | Director | M-Exempt | D | Restricted Stock Unit | 4,475 | 0.00 | — | 0 | D | ↗ |
| 2026-02-18 | Sensenig Bethany | Director | A-Award | A | Restricted Stock Unit | 2,989 | 0.00 | — | 2,989 | D | ↗ |
| 2026-02-18 | Rubin Jonathan | Officer | A-Award | A | Restricted Stock Unit | 3,000 | 0.00 | — | 3,000 | D | ↗ |
| 2026-02-18 | NEWHALL CHARLES W III | Director | A-Award | A | Restricted Stock Unit | 2,989 | 0.00 | — | 2,989 | D | ↗ |
| 2026-02-18 | Mottola Frank | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 13,500 | 50.20 | 677.7K | 13,500 | D | ↗ |
| 2026-02-18 | Khattar Jack A. | Director / Officer | A-Award | A | Employee Stock Option (Right to Buy) | 341,610 | 50.20 | 17.15M | 341,610 | D | ↗ |
| 2026-02-18 | Hudson Frederick M. | Director | A-Award | A | Restricted Stock Unit | 2,989 | 0.00 | — | 2,989 | D | ↗ |
| 2026-02-18 | GEMAYEL GEORGES | Director | A-Award | A | Director Stock Option (Right to Buy) | 4,977 | 50.20 | 249.8K | 4,977 | D | ↗ |
| 2026-02-18 | DEC TIMOTHY C | Officer | A-Award | A | Restricted Stock Unit | 3,000 | 0.00 | — | 3,000 | D | ↗ |
| 2026-02-18 | Bhatt Padmanabh P. | Officer | A-Award | A | Restricted Stock Unit | 3,000 | 0.00 | — | 3,000 | D | ↗ |
| 2026-02-18 | Barlow Carrolee | Director | A-Award | A | Restricted Stock Unit | 2,989 | 0.00 | — | 2,989 | D | ↗ |
| 2026-01-09 | Hudson Frederick M. | Director | M-Exempt | A | Common Stock | 15,000 | 12.98 | 194.7K | 61,307 | D | ↗ |
| 2025-12-19 | Mottola Frank | Officer | S-Sale | D | Common Stock | 15,000 | 50.47 | 757.1K | 15,496 | D | ↗ |
| 2025-12-18 | Bhatt Padmanabh P. | Officer | M-Exempt | A | Common Stock | 1,500 | 0.00 | — | 15,218 | D | ↗ |
| 2025-11-21 | NEWHALL CHARLES W III | Director | M-Exempt | A | Common Stock | 15,000 | 12.98 | 194.7K | 119,644 | D | ↗ |
| 2025-11-13 | Bhatt Padmanabh P. | Officer | A-Award | A | Performance Share Unit | 1,500 | 0.00 | — | 1,500 | D | ↗ |
| 2025-10-09 | NEWHALL CHARLES W III | Director | S-Sale | D | Common Stock | 1,200 | 51.55 | 61.9K | 104,644 | D | ↗ |
| 2025-10-09 | Khattar Jack A. | Director / Officer | M-Exempt | D | Employee Stock Option (Right to Buy) | 81,250 | 25.30 | 2.06M | 0 | D | ↗ |
| 2025-10-02 | Khattar Jack A. | Director / Officer | M-Exempt | D | Performance Share Units | 19,320 | 0.00 | — | 0 | D | ↗ |
| 2025-10-01 | Khattar Jack A. | Director / Officer | M-Exempt | A | Common Stock | 53,785 | 25.30 | 1.36M | 1,201,043 | D | ↗ |
| 2025-09-30 | Khattar Jack A. | Director / Officer | M-Exempt | A | Common Stock | 11,510 | 25.30 | 291.2K | 1,155,846 | D | ↗ |
| 2025-09-29 | Khattar Jack A. | Director / Officer | M-Exempt | D | Employee Stock Option (Right to Buy) | 13,688 | 25.30 | 346.3K | 148,812 | D | ↗ |
| 2025-09-25 | Rubin Jonathan | Officer | M-Exempt | A | Common Stock | 1,875 | 0.00 | — | 11,855 | D | ↗ |
| 2025-09-23 | Khattar Jack A. | Director / Officer | M-Exempt | A | Common Stock | 47,940 | 12.98 | 622.3K | 1,170,396 | D | ↗ |
| 2025-09-22 | Khattar Jack A. | Director / Officer | M-Exempt | D | Employee Stock Option (Right to Buy) | 27,060 | 12.98 | 351.2K | 47,940 | D | ↗ |
| 2025-09-12 | Mottola Frank | Officer | M-Exempt | A | Common Stock | 5,000 | 39.40 | 197.0K | 20,496 | D | ↗ |
| 2025-09-10 | Rubin Jonathan | Officer | A-Award | A | Performance Share Unit | 1,875 | 0.00 | — | 1,875 | D | ↗ |
| 2025-09-10 | Khattar Jack A. | Director / Officer | A-Award | A | Performance Share Unit | 20,000 | 0.00 | — | 20,000 | D | ↗ |
| 2025-09-08 | Khattar Jack A. | Director / Officer | S-Sale | D | Common Stock | 6,322 | 46.29 | 292.6K | 1,111,983 | D | ↗ |
| 2025-09-05 | Khattar Jack A. | Director / Officer | M-Exempt | D | Employee Stock Option (Right to Buy) | 73,176 | 25.30 | 1.85M | 170,574 | D | ↗ |
| 2025-08-28 | Khattar Jack A. | Director / Officer | M-Exempt | A | Common Stock | 38,779 | 12.98 | 503.4K | 1,116,783 | D | ↗ |
| 2025-08-27 | NEWHALL CHARLES W III | Director | S-Sale | D | Common Stock | 3,588 | 45.01 | 161.5K | 129,644 | D | ↗ |
| 2025-08-27 | Khattar Jack A. | Director / Officer | M-Exempt | A | Common Stock | 17,195 | 12.98 | 223.2K | 1,088,654 | D | ↗ |
| 2025-08-25 | NEWHALL CHARLES W III | Director | S-Sale | D | Common Stock | 1,000 | 45.00 | 45.0K | 133,232 | D | ↗ |
| 2025-08-25 | Mottola Frank | Officer | M-Exempt | D | Employee Stock Option (Right to Buy) | 14,000 | 12.98 | 181.7K | 0 | D | ↗ |
| 2025-08-25 | Khattar Jack A. | Director / Officer | M-Exempt | D | Employee Stock Option (Right to Buy) | 1,611 | 12.98 | 20.9K | 130,974 | D | ↗ |
| 2025-08-25 | Bhatt Padmanabh P. | Officer | F-InKind | D | Common Stock | 581 | 41.46 | 24.1K | 13,718 | D | ↗ |
| 2025-08-22 | NEWHALL CHARLES W III | Director | S-Sale | D | Common Stock | 1,412 | 45.00 | 63.5K | 134,232 | D | ↗ |
| 2025-08-22 | Khattar Jack A. | Director / Officer | S-Sale | D | Common Stock | 1,500 | 45.00 | 67.5K | 1,070,848 | D | ↗ |
| 2025-08-22 | DEC TIMOTHY C | Officer | S-Sale | D | Common Stock | 11,780 | 44.49 | 524.1K | 1,246 | D | ↗ |
| 2025-08-14 | Sensenig Bethany | Director | S-Sale | D | Common Stock | 5,369 | 42.25 | 226.8K | 0 | D | ↗ |
| 2025-08-14 | Hudson Frederick M. | Director | S-Sale | D | Common Stock | 7,457 | 42.26 | 315.1K | 46,307 | D | ↗ |
| 2025-08-07 | Bhatt Padmanabh P. | Officer | A-Award | A | Performance Share Unit | 1,250 | 0.00 | — | 1,250 | D | ↗ |
| 2025-08-06 | Khattar Jack A. | Director / Officer | M-Exempt | A | Common Stock | 81,250 | 25.30 | 2.06M | 1,133,433 | D | ↗ |
| 2025-04-02 | Khattar Jack A. | Director / Officer | J-Other | A | Common Stock | 16,850 | 0.00 | — | 1,008,683 | D | ↗ |
| 2025-03-10 | Khattar Jack A. | Director / Officer | F-InKind | D | Common Stock | 16,805 | 32.06 | 538.8K | 991,833 | D | ↗ |
| 2025-03-10 | DEC TIMOTHY C | Officer | F-InKind | D | Common Stock | 1,062 | 32.06 | 34.0K | 11,836 | D | ↗ |
| 2025-03-07 | Mottola Frank | Officer | M-Exempt | A | Common Stock | 2,625 | 0.00 | — | 16,507 | D | ↗ |
| 2025-03-07 | Khattar Jack A. | Director / Officer | M-Exempt | A | Common Stock | 38,640 | 0.00 | — | 992,219 | D | ↗ |
| 2025-03-05 | Rubin Jonathan | Officer | F-InKind | D | Common Stock | 577 | 33.05 | 19.1K | 10,212 | D | ↗ |
| 2025-03-05 | Mottola Frank | Officer | F-InKind | D | Common Stock | 945 | 33.05 | 31.2K | 13,882 | D | ↗ |
| 2025-03-05 | DEC TIMOTHY C | Officer | F-InKind | D | Common Stock | 1,587 | 33.05 | 52.5K | 12,228 | D | ↗ |
| 2025-03-05 | Bhatt Padmanabh P. | Officer | F-InKind | D | Common Stock | 575 | 33.05 | 19.0K | 12,704 | D | ↗ |
| 2025-02-28 | Khattar Jack A. | Director / Officer | A-Award | A | Performance Share Unit | 35,000 | 0.00 | — | 35,000 | D | ↗ |
| 2025-02-28 | DEC TIMOTHY C | Officer | A-Award | A | Performance Share Unit | 1,800 | 0.00 | — | 1,800 | D | ↗ |
| 2025-02-26 | Mottola Frank | Officer | M-Exempt | A | Common Stock | 3,750 | 0.00 | — | 17,683 | D | ↗ |
| 2025-02-23 | Rubin Jonathan | Officer | D-Return | D | Restricted Stock Unit | 1,250 | 0.00 | — | 2,500 | D | ↗ |
| 2025-02-23 | Mottola Frank | Officer | A-Award | A | Common Stock | 1,875 | 0.00 | — | 12,899 | D | ↗ |
| 2025-02-23 | DEC TIMOTHY C | Officer | A-Award | A | Common Stock | 2,500 | 0.00 | — | 14,091 | D | ↗ |
| 2025-02-23 | Bhatt Padmanabh P. | Officer | D-Return | D | Restricted Stock Unit | 1,250 | 0.00 | — | 2,500 | D | ↗ |
| 2025-02-22 | Sensenig Bethany | Director | A-Award | A | Common Stock | 5,369 | 0.00 | — | 5,369 | D | ↗ |
| 2025-02-22 | Rubin Jonathan | Officer | A-Award | A | Common Stock | 1,250 | 0.00 | — | 9,853 | D | ↗ |
| 2025-02-22 | NEWHALL CHARLES W III | Director | D-Return | D | Restricted Stock Units | 5,369 | 0.00 | — | 0 | D | ↗ |
| 2025-02-22 | Mottola Frank | Officer | A-Award | A | Common Stock | 750 | 0.00 | — | 9,774 | D | ↗ |
| 2025-02-22 | Hudson Frederick M. | Director | D-Return | D | Restricted Stock Units | 5,369 | 0.00 | — | 0 | D | ↗ |
| 2025-02-22 | GEMAYEL GEORGES | Director | A-Award | A | Common Stock | 5,369 | 0.00 | — | 18,684 | D | ↗ |
| 2025-02-22 | DEC TIMOTHY C | Officer | A-Award | A | Common Stock | 3,000 | 0.00 | — | 11,591 | D | ↗ |
| 2025-02-22 | Bhatt Padmanabh P. | Officer | A-Award | A | Common Stock | 1,250 | 0.00 | — | 12,939 | D | ↗ |
| 2025-02-22 | Barlow Carrolee | Director | A-Award | A | Common Stock | 5,369 | 0.00 | — | 22,570 | D | ↗ |
| 2025-02-21 | Rubin Jonathan | Officer | M-Exempt | D | Performance Share Units | 1,875 | 0.00 | — | 0 | D | ↗ |
| 2025-02-21 | Mottola Frank | Officer | M-Exempt | D | Performance Share Units | 1,125 | 0.00 | — | 0 | D | ↗ |
| 2025-02-21 | Bhatt Padmanabh P. | Officer | M-Exempt | D | Performance Share Units | 1,650 | 0.00 | — | 0 | D | ↗ |
| 2025-02-20 | Khattar Jack A. | Director / Officer | A-Award | A | Employee Stock Option (Right to Buy) | 331,660 | 34.59 | 11.47M | 331,660 | D | ↗ |
| 2025-02-19 | Sensenig Bethany | Director | A-Award | A | Restricted Stock Unit | 4,475 | 0.00 | — | 4,475 | D | ↗ |
| 2025-02-19 | Rubin Jonathan | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 20,000 | 33.52 | 670.4K | 20,000 | D | ↗ |
| 2025-02-19 | NEWHALL CHARLES W III | Director | A-Award | A | Restricted Stock Unit | 4,475 | 0.00 | — | 4,475 | D | ↗ |
| 2025-02-19 | Mottola Frank | Officer | A-Award | A | Restricted Stock Unit | 4,500 | 0.00 | — | 4,500 | D | ↗ |
| 2025-02-19 | Hudson Frederick M. | Director | A-Award | A | Restricted Stock Unit | 4,475 | 0.00 | — | 4,475 | D | ↗ |
| 2025-02-19 | GEMAYEL GEORGES | Director | A-Award | A | Director Stock Option (Right to Buy) | 7,296 | 33.52 | 244.6K | 7,296 | D | ↗ |
| 2025-02-19 | DEC TIMOTHY C | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 40,000 | 33.52 | 1.34M | 40,000 | D | ↗ |
| 2025-02-19 | Bhatt Padmanabh P. | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 20,000 | 33.52 | 670.4K | 20,000 | D | ↗ |
| 2025-02-19 | Barlow Carrolee | Director | A-Award | A | Restricted Stock Unit | 4,475 | 0.00 | — | 4,475 | D | ↗ |
| 2025-02-17 | Mottola Frank | Officer | A-Award | A | Performance Share Units | 2,625 | 0.00 | — | 2,625 | D | ↗ |
| 2025-02-17 | Khattar Jack A. | Director / Officer | A-Award | A | Performance Share Units | 38,640 | 0.00 | — | 38,640 | D | ↗ |
| 2025-02-05 | Mottola Frank | Officer | A-Award | A | Performance Share Units | 3,750 | 0.00 | — | 3,750 | D | ↗ |
| 2025-02-04 | Bhatt Padmanabh P. | Officer | S-Sale | D | Common Stock | 9,477 | 39.70 | 376.2K | 10,149 | D | ↗ |
| 2025-01-28 | Rubin Jonathan | Officer | A-Award | A | Performance Share Units | 1,875 | 0.00 | — | 1,875 | D | ↗ |
| 2025-01-28 | Mottola Frank | Officer | A-Award | A | Performance Share Units | 1,125 | 0.00 | — | 1,125 | D | ↗ |
| 2025-01-28 | Bhatt Padmanabh P. | Officer | S-Sale | D | Common Stock | 700 | 39.62 | 27.7K | 10,149 | D | ↗ |
| 2025-01-27 | Bhatt Padmanabh P. | Officer | M-Exempt | D | Employee Stock Option (Right to Buy) | 2,573 | 29.61 | 76.2K | 10,177 | D | ↗ |
| 2025-01-22 | Hudson Frederick M. | Director | M-Exempt | A | Common Stock | 20,000 | 9.13 | 182.6K | 48,395 | D | ↗ |
| 2024-12-27 | Rubin Jonathan | Officer | M-Exempt | D | Performance Share Unit | 1,875 | 0.00 | — | 0 | D | ↗ |
| 2024-12-27 | Khattar Jack A. | Director / Officer | F-InKind | D | Common Stock | 18,567 | 35.59 | 660.8K | 946,245 | D | ↗ |
| 2024-12-23 | Rubin Jonathan | Officer | A-Award | A | Performance Share Unit | 1,875 | 0.00 | — | 1,875 | D | ↗ |
| 2024-12-23 | Khattar Jack A. | Director / Officer | A-Award | A | Performance Share Unit | 38,640 | 0.00 | — | 38,640 | D | ↗ |
| 2024-12-03 | Bhatt Padmanabh P. | Officer | S-Sale | D | Common Stock | 12,745 | 36.68 | 467.5K | 9,679 | D | ↗ |
| 2024-11-11 | NEWHALL CHARLES W III | Director | M-Exempt | A | Common Stock | 20,000 | 9.13 | 182.6K | 140,975 | D | ↗ |
| 2024-11-08 | Khattar Jack A. | Director / Officer | M-Exempt | D | Employee Stock Option (Right to Buy) | 125,000 | 9.13 | 1.14M | 0 | D | ↗ |
| 2024-11-08 | Hudson Frederick M. | Director | S-Sale | D | Common Stock | 8,722 | 36.28 | 316.4K | 28,395 | D | ↗ |
| 2024-11-08 | GEMAYEL GEORGES | Director | M-Exempt | D | Director Stock Option (Right to Buy) | 10,787 | 11.46 | 123.6K | 0 | D | ↗ |
| 2024-11-07 | Mottola Frank | Officer | M-Exempt | D | Employee Stock Option (Right to Buy) | 15,000 | 9.13 | 137.0K | 0 | D | ↗ |
| 2024-11-07 | Khattar Jack A. | Director / Officer | M-Exempt | D | Employee Stock Option (Right to Buy) | 125,000 | 9.13 | 1.14M | 125,000 | D | ↗ |
| 2024-11-07 | GEMAYEL GEORGES | Director | S-Sale | D | Common Stock | 14,213 | 36.62 | 520.5K | 13,315 | D | ↗ |
| 2024-09-13 | GEMAYEL GEORGES | Director | M-Exempt | D | Director Stock Option (Right to Buy) | 10,000 | 11.46 | 114.6K | 25,000 | — | ↗ |
| 2024-09-03 | Khattar Jack A. | Director / Officer | M-Exempt | A | Common Stock | 21,000 | 0.00 | — | 936,217 | — | ↗ |
| 2024-08-27 | Khattar Jack A. | Director / Officer | A-Award | A | Performance Share Unit | 21,000 | 0.00 | — | 21,000 | — | ↗ |
| 2024-08-20 | Bhatt Padmanabh P. | Officer | F-InKind | D | Common Stock | 572 | 29.57 | 16.9K | 9,679 | — | ↗ |
| 2024-08-01 | Bhatt Padmanabh P. | Officer | A-Award | A | Performance Share Unit | 1,250 | 0.00 | — | 1,250 | — | ↗ |
| 2024-03-21 | Bhatt Padmanabh P. | Officer | M-Exempt | A | Common Stock | 14,491 | 25.30 | 366.6K | 23,061 | — | ↗ |
| 2024-03-20 | Bhatt Padmanabh P. | Officer | M-Exempt | D | Employee Stock Option (Right to Buy) | 400 | 25.30 | 10.1K | 27,236 | — | ↗ |
| 2024-03-19 | Bhatt Padmanabh P. | Officer | M-Exempt | D | Employee Stock Option (Right to Buy) | 12,364 | 25.30 | 312.8K | 27,636 | — | ↗ |
| 2024-03-13 | Bhatt Padmanabh P. | Officer | M-Exempt | D | Employee Stock Option (Right to Buy) | 26,250 | 23.99 | 629.7K | 8,750 | — | ↗ |
| 2024-03-12 | Bhatt Padmanabh P. | Officer | M-Exempt | D | Employee Stock Option (Right to Buy) | 3,884 | 12.98 | 50.4K | 36,116 | — | ↗ |
| 2024-02-28 | Mottola Frank | Officer | M-Exempt | D | Performance Share Unit | 990 | 0.00 | — | 0 | — | ↗ |
| 2024-02-28 | Khattar Jack A. | Director / Officer | M-Exempt | D | Performance Share Unit | 35,000 | 0.00 | — | 0 | — | ↗ |
| 2024-02-26 | Bhatt Padmanabh P. | Officer | M-Exempt | A | Common Stock | 5,000 | 9.13 | 45.7K | 13,570 | — | ↗ |
| 2024-02-23 | SIEBERT JOHN M | Director | A-Award | A | Common Stock | 3,886 | 0.00 | — | 87,943 | — | ↗ |
| 2024-02-23 | Rubin Jonathan | Officer | A-Award | A | Common Stock | 1,250 | 0.00 | — | 5,208 | — | ↗ |
| 2024-02-23 | NEWHALL CHARLES W III | Director | D-Return | D | Restricted Stock Unit | 3,886 | 0.00 | — | 0 | — | ↗ |
| 2024-02-23 | Mottola Frank | Officer | D-Return | D | Restricted Stock Unit | 1,875 | 0.00 | — | 5,625 | — | ↗ |
| 2024-02-23 | Martin Tami Tillotson | Officer | A-Award | A | Common Stock | 1,250 | 0.00 | — | 87,418 | — | ↗ |
| 2024-02-23 | Hudson Frederick M. | Director | A-Award | A | Common Stock | 3,886 | 0.00 | — | 37,117 | — | ↗ |
| 2024-02-23 | GEMAYEL GEORGES | Director | D-Return | D | Restricted Stock Unit | 3,886 | 0.00 | — | 0 | — | ↗ |
| 2024-02-23 | DEC TIMOTHY C | Officer | A-Award | A | Common Stock | 2,500 | 0.00 | — | 8,504 | — | ↗ |
| 2024-02-23 | Bhatt Padmanabh P. | Officer | D-Return | D | Restricted Stock Unit | 1,250 | 0.00 | — | 3,750 | — | ↗ |
| 2024-02-23 | Barlow Carrolee | Director | D-Return | D | Restricted Stock Units | 3,886 | 0.00 | — | 0 | — | ↗ |
| 2024-02-22 | Sensenig Bethany | Director | A-Award | A | Director Stock Option (Right to Buy) | 8,252 | 27.94 | 230.6K | 8,252 | — | ↗ |
| 2024-02-22 | SIEBERT JOHN M | Director | A-Award | A | Restricted Stock Units | 5,369 | 0.00 | — | 5,369 | — | ↗ |
| 2024-02-22 | Rubin Jonathan | Officer | A-Award | A | Restricted Stock Unit | 5,000 | 0.00 | — | 5,000 | — | ↗ |
| 2024-02-22 | NEWHALL CHARLES W III | Director | A-Award | A | Director Stock Option (Right to Buy) | 8,252 | 27.94 | 230.6K | 8,252 | — | ↗ |
| 2024-02-22 | Mottola Frank | Officer | A-Award | A | Restricted Stock Unit | 5,000 | 0.00 | — | 5,000 | — | ↗ |
| 2024-02-22 | Martin Tami Tillotson | Officer | D-Return | D | Restricted Stock Units | 750 | 0.00 | — | 1,500 | — | ↗ |
| 2024-02-22 | Khattar Jack A. | Director / Officer | A-Award | A | Employee Stock Option (Right to Buy) | 322,000 | 27.94 | 9.00M | 322,000 | — | ↗ |
| 2024-02-22 | Hudson Frederick M. | Director | A-Award | A | Director Stock Option (Right to Buy) | 8,252 | 27.94 | 230.6K | 8,252 | — | ↗ |
| 2024-02-22 | GEMAYEL GEORGES | Director | A-Award | A | Director Stock Option (Right to Buy) | 8,252 | 27.94 | 230.6K | 8,252 | — | ↗ |
| 2024-02-22 | DEC TIMOTHY C | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 50,000 | 27.94 | 1.40M | 50,000 | — | ↗ |
| 2024-02-22 | Bhatt Padmanabh P. | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 20,000 | 27.94 | 558.8K | 20,000 | — | ↗ |
| 2024-02-22 | Barlow Carrolee | Director | A-Award | A | Director Stock Option (Right to Buy) | 8,252 | 27.94 | 230.6K | 8,252 | — | ↗ |
| 2024-02-12 | Khattar Jack A. | Director / Officer | J-Other | D | Common Stock | 16,500 | 0.00 | — | 1,022,450 | — | ↗ |
| 2024-01-10 | Martin Tami Tillotson | Officer | S-Sale | D | Common Stock | 8,000 | 27.91 | 223.3K | 85,664 | — | ↗ |
| 2023-12-22 | Rubin Jonathan | Officer | M-Exempt | A | Common Stock | 600 | 0.00 | — | 3,447 | — | ↗ |
| 2023-12-22 | Khattar Jack A. | Director / Officer | M-Exempt | A | Common Stock | 25,000 | 0.00 | — | 892,463 | — | ↗ |
| 2023-12-14 | Rubin Jonathan | Officer | A-Award | A | Performance Share Unit | 600 | 0.00 | — | 600 | — | ↗ |
| 2023-12-14 | Khattar Jack A. | Director / Officer | A-Award | A | Performance Share Unit | 25,000 | 0.00 | — | 25,000 | — | ↗ |
| 2023-11-16 | NEWHALL CHARLES W III | Director | M-Exempt | A | Common Stock | 7,457 | 9.24 | 68.9K | 119,589 | — | ↗ |
| 2023-11-15 | Hudson Frederick M. | Director | S-Sale | D | Common Stock | 3,882 | 28.50 | 110.6K | 38,442 | — | ↗ |
| 2023-11-14 | Mottola Frank | Officer | M-Exempt | A | Common Stock | 2,000 | 9.24 | 18.5K | 6,791 | — | ↗ |
| 2023-10-13 | DEC TIMOTHY C | Officer | M-Exempt | A | Common Stock | 4,000 | 0.00 | — | 7,000 | — | ↗ |
| 2023-10-04 | DEC TIMOTHY C | Officer | A-Award | A | Performance Share Unit | 4,000 | 0.00 | — | 4,000 | — | ↗ |
| 2023-09-07 | Khattar Jack A. | Director / Officer | M-Exempt | A | Common Stock | 35,000 | 0.00 | — | 884,267 | — | ↗ |
| 2023-09-07 | Bhatt Padmanabh P. | Officer | M-Exempt | A | Common Stock | 2,500 | 0.00 | — | 8,347 | — | ↗ |
| 2023-08-30 | Martin Tami Tillotson | Officer | M-Exempt | A | Common Stock | 8,100 | 23.99 | 194.3K | 93,349 | — | ↗ |
| 2023-08-25 | Martin Tami Tillotson | Officer | S-Sale | D | Common Stock | 5,135 | 31.59 | 162.2K | 85,249 | — | ↗ |
| 2023-08-23 | Khattar Jack A. | Director / Officer | A-Award | A | Performance Share Unit | 35,000 | 0.00 | — | 35,000 | — | ↗ |
| 2023-08-23 | Bhatt Padmanabh P. | Officer | A-Award | A | Performance Share Unit | 2,500 | 0.00 | — | 2,500 | — | ↗ |
| 2023-08-17 | Sensenig Bethany | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-05-11 | Khattar Jack A. | Director / Officer | M-Exempt | A | Common Stock | 31,250 | 0.00 | — | 864,272 | — | ↗ |
| 2023-05-11 | DEC TIMOTHY C | Officer | M-Exempt | A | Common Stock | 1,500 | 0.00 | — | 3,359 | — | ↗ |
| 2023-05-11 | Bhatt Padmanabh P. | Officer | M-Exempt | A | Common Stock | 750 | 0.00 | — | 5,497 | — | ↗ |
| 2023-05-04 | Khattar Jack A. | Director / Officer | A-Award | A | Performance Share Unit | 31,250 | 0.00 | — | 31,250 | — | ↗ |
| 2023-05-04 | DEC TIMOTHY C | Officer | A-Award | A | Performance Share Units | 1,500 | 0.00 | — | 1,500 | — | ↗ |
| 2023-05-04 | Bhatt Padmanabh P. | Officer | A-Award | A | Performance Share Unit | 750 | 0.00 | — | 750 | — | ↗ |
| 2023-04-11 | Bhatt Padmanabh P. | Officer | A-Award | A | Common Stock | 1,500 | 0.00 | — | 4,747 | — | ↗ |
| 2023-03-14 | Mottola Frank | Officer | S-Sale | D | Common Stock | 4,780 | 35.99 | 172.0K | 4,737 | — | ↗ |
| 2023-03-14 | Khattar Jack A. | Director / Officer | M-Exempt | D | Performance Share Unit | 20,000 | 0.00 | — | 0 | — | ↗ |
| 2023-03-14 | DEC TIMOTHY C | Officer | F-InKind | D | Common Stock | 789 | 38.65 | 30.5K | 2,052 | — | ↗ |
| 2023-02-23 | SIEBERT JOHN M | Director | A-Award | A | Director Stock Option (Right to Buy) | 6,293 | 38.60 | 242.9K | 6,293 | — | ↗ |
| 2023-02-23 | Rubin Jonathan | Officer | A-Award | A | Restricted Stock Units | 5,000 | 0.00 | — | 5,000 | — | ↗ |
| 2023-02-23 | NEWHALL CHARLES W III | Director | A-Award | A | Restricted Stock Units | 3,886 | 0.00 | — | 3,886 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-72.7K
Shares Outstanding
57.58M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Jack A. Khattar Chief Executive Officer, President & Secretary | 1.04M | — | 6.54M | 7.03M | 846.9K | 52.1K | 15.50M | 87.52% | ↗ |
| 2 | 2025 | Timothy C. Dec Senior Vice President, Chief Financial Officer | 504.9K | — | 315.0K | 822.4K | 233.9K | 40.1K | 1.92M | 59.35% | ↗ |
| 3 | 2025 | Jonathan Rubin, MD Senior Vice President, Chief Medical Officer Research and Development | 485.1K | — | 315.0K | 411.2K | 197.8K | 39.5K | 1.45M | 50.13% | ↗ |
| 4 | 2025 | Padmanabh P. Bhatt, Ph.D. Senior Vice President, Intellectual Property, Chief Scientific Officer | 455.9K | — | 315.0K | 411.2K | 168.2K | 41.1K | 1.39M | 52.19% | ↗ |
| 5 | 2025 | Frank Mottola Senior Vice President, Chief Technical Operations Officer | 412.5K | — | 315.0K | 411.2K | 173.9K | 48.0K | 1.36M | 53.37% | ↗ |
| 6 | 2024 | Jack A. Khattar Chief Executive Officer, President & Secretary | 1.00M | — | 5.20M | 5.57M | 826.3K | 46.8K | 12.64M | 85.17% | ↗ |
| 7 | 2024 | Timothy C. Dec Senior Vice President, Chief Financial Officer | 485.5K | — | 658.2K | 864.5K | 229.2K | 40.3K | 2.28M | 66.85% | ↗ |
| 8 | 2024 | Frank Mottola Senior Vice President, Quality GMP Operations, Information Technology and Regulatory Affairs | 378.4K | — | 341.5K | 432.3K | 140.0K | 53.2K | 1.69M | 45.87% | ↗ |
| 9 | 2024 | Jonathan Rubin, MD Senior Vice President, Chief Medical Officer Research and Development | 466.4K | — | 341.5K | 432.3K | 192.5K | 37.4K | 1.47M | 52.64% | ↗ |
| 10 | 2024 | Frank Mottola Senior Vice President, Chief Technical Operations Officer | 377.4K | — | 341.5K | 432.3K | 140.0K | 43.8K | 1.33M | 57.96% | ↗ |
| 11 | 2024 | Padmanabh P. Bhatt, Ph.D. Senior Vice President, Intellectual Property, Chief Scientific Officer | 440.5K | — | 274.3K | 345.8K | 163.4K | 37.6K | 1.26M | 49.15% | ↗ |
| 12 | 2023 | Jack A. Khattar Chief Executive Officer, President & Secretary | 963.0K | — | 4.76M | 6.68M | 830.6K | 49.3K | 13.28M | 86.12% | ↗ |
| 13 | 2023 | Frank Mottola Senior Vice President, Quality GMP Operations, Information Technology and Regulatory Affairs | 352.7K | — | 544.5K | 715.2K | 129.4K | 44.4K | 1.79M | 70.52% | ↗ |
| 14 | 2023 | Frank Mottola Senior Vice President, Chief Technical Operations Officer | 352.7K | — | 544.5K | 715.2K | 129.4K | 44.4K | 1.79M | 70.52% | ↗ |
| 15 | 2023 | Jonathan Rubin, MD Senior Vice President, Chief Medical Officer Research and Development | 440.0K | — | 448.0K | 476.8K | 184.4K | 38.1K | 1.59M | 58.26% | ↗ |
| 16 | 2023 | Padmanabh P. Bhatt, Ph.D. Senior Vice President, Intellectual Property, Chief Scientific Officer | 427.7K | — | 363.0K | 476.8K | 163.2K | 37.5K | 1.47M | 57.20% | ↗ |
| 17 | 2023 | Timothy C. Dec Senior Vice President, Chief Financial Officer | 453.8K | — | 726.0K | 953.6K | 210.6K | 39.6K | 5.00 | 33,592,000.00% | ↗ |
| 18 | 2022 | Jack A. Khattar Chief Executive Officer, President & Secretary | 913.5K | — | 3.62M | 4.77M | 685.1K | 30.3K | 10.01M | 83.73% | ↗ |
| 19 | 2022 | Timothy C. Dec Senior Vice President, Chief Financial Officer | 412.5K | — | 151.2K | 476.8K | 178.2K | 44.7K | 1.26M | 49.70% | ↗ |
| 20 | 2022 | Jonathan Rubin, MD Senior Vice President, Chief Medical Officer Research and Development | 412.0K | — | 183.4K | 476.8K | 149.3K | 33.4K | 1.25M | 52.61% | ↗ |
| 21 | 2022 | Padmanabh P. Bhatt, Ph.D. Senior Vice President, Intellectual Property, Chief Scientific Officer | 415.2K | — | 183.4K | 343.3K | 141.0K | 38.0K | 1.12M | 46.99% | ↗ |
| 22 | 2022 | Frank Mottola Senior Vice President, Quality GMP Operations and IT | 342.4K | — | 183.4K | 343.3K | 109.1K | 39.4K | 1.03M | 51.13% | ↗ |
| 23 | 2022 | Frank Mottola Senior Vice President, Quality GMP Operations, Information Technology and Regulatory Affairs | 342.4K | — | 183.4K | 343.3K | 109.1K | 39.4K | 1.03M | 51.13% | ↗ |
| 24 | 2021 | Jack A. Khattar Chief Executive Officer, President & Secretary | 870.0K | — | 2.94M | 3.40M | 887.4K | 18.1K | 8.12M | 78.12% | ↗ |
| 25 | 2021 | Timothy C. Dec Senior Vice President, Chief Financial Officer | 135.1K | — | — | 1.24M | 72.3K | 7.5K | 1.45M | 85.22% | ↗ |
| 26 | 2021 | Jonathan Rubin, MD Senior Vice President, Chief Medical Officer Research and Development | 385.0K | — | 45.7K | 425.0K | 143.7K | 29.0K | 1.03M | 45.77% | ↗ |
| 27 | 2021 | Padmanabh P. Bhatt, Ph.D. Senior Vice President, Intellectual Property, Chief Scientific Officer | 403.1K | — | 45.7K | 289.0K | 158.9K | 36.6K | 933.3K | 35.86% | ↗ |
| 28 | 2021 | Tami Martin, R.N., Esq. Senior Vice President, Regulatory Affairs | 336.2K | — | 45.7K | 289.0K | 129.7K | 42.6K | 843.2K | 39.69% | ↗ |
| 29 | 2021 | James P. Kelly Former Executive Vice President, Chief Financial Officer | 292.2K | — | — | — | — | 43.9K | 636.7K | 0.00% | ↗ |
| 30 | 2020 | Jack A. Khattar Chief Executive Officer, President & Secretary | 836.4K | — | 1.03M | 3.96M | 815.5K | 28.5K | 6.67M | 74.80% | ↗ |
| 31 | 2020 | James P. Kelly Executive Vice President, Chief Financial Officer | 102.9K | — | — | 1.64M | 50.9K | 6.1K | 1.80M | 91.12% | ↗ |
| 32 | 2020 | James P. Kelly Former Executive Vice President, Chief Financial Officer | 102.9K | — | — | 1.64M | 50.9K | 6.1K | 1.80M | 91.12% | ↗ |
| 33 | 2020 | Stefan K.F. Schwabe, M.D., Ph.D. Executive Vice President of Research and Development, Chief Medical Officer | 413.0K | — | — | 703.3K | — | 73.3K | 1.19M | 59.12% | ↗ |
| 34 | 2020 | Gregory S. Patrick Senior Vice President, Chief Financial Officer | 353.1K | — | — | 703.3K | — | 96.5K | 1.15M | 61.01% | ↗ |
| 35 | 2020 | Padmanabh P. Bhatt, Ph.D. Senior Vice President, Intellectual Property, Chief Scientific Officer | 391.4K | — | — | 492.3K | 161.6K | 29.2K | 1.07M | 45.82% | ↗ |
| 36 | 2020 | Tami Martin, R.N., Esq. Senior Vice President, Regulatory Affairs | 326.4K | — | — | 309.4K | 131.2K | 37.6K | 804.6K | 38.46% | ↗ |
| 37 | 2020 | Tami Martin, R.N., Esq. Senior Vice President, Regulatory | 326.4K | — | — | 309.4K | 131.2K | 37.6K | 804.6K | 38.46% | ↗ |
| 38 | 2019 | Jack A. Khattar Chief Executive Officer, President & Secretary | 812.0K | — | — | 6.64M | 593.8K | 79.7K | 8.12M | 81.71% | ↗ |
| 39 | 2019 | Stefan K.F. Schwabe, M.D., Ph.D. Executive Vice President of Research and Development, Chief Medical Officer | 401.2K | — | — | 885.0K | 150.9K | 32.0K | 1.47M | 60.24% | ↗ |
| 40 | 2019 | Gregory S. Patrick Senior Vice President, Chief Financial Officer | 383.0K | — | — | 885.0K | 145.4K | 27.1K | 1.44M | 61.43% | ↗ |
| 41 | 2019 | Padmanabh P. Bhatt, Ph.D. Senior Vice President, Intellectual Property, Chief Scientific Officer | 380.0K | — | — | 774.4K | 131.0K | 26.2K | 1.31M | 59.04% | ↗ |
| 42 | 2019 | Tami Martin, R.N., Esq. Senior Vice President, Regulatory | 316.9K | — | — | 424.5K | 91.4K | 42.0K | 874.8K | 48.53% | ↗ |
| 43 | 2019 | Tami Martin, R.N., Esq. Senior Vice President, Regulatory Affairs | 316.9K | — | — | 424.5K | 91.4K | 42.0K | 874.8K | 48.53% | ↗ |
| 44 | 2018 | Jack A. Khattar Chief Executive Officer, President & Secretary | 724.0K | — | — | 5.80M | 635.0K | 63.0K | 7.22M | 80.31% | ↗ |
| 45 | 2018 | Stefan K.F. Schwabe, M.D., Ph.D. Executive Vice President of Research and Development, Chief Medical Officer | 390.0K | — | — | 695.8K | 163.0K | 30.4K | 1.28M | 54.39% | ↗ |
| 46 | 2018 | Gregory S. Patrick Senior Vice President, Chief Financial Officer | 362.0K | — | — | 695.8K | 158.0K | 19.8K | 1.24M | 56.31% | ↗ |
| 47 | 2018 | Padmanabh P. Bhatt, Ph.D. Senior Vice President, Intellectual Property, Chief Scientific Officer | 369.0K | — | — | 695.8K | 140.0K | 25.0K | 1.23M | 56.58% | ↗ |
| 48 | 2018 | Victor Vaughn Former Senior Vice President of Sales and Marketing | 155.7K | — | — | 765.4K | — | 22.1K | 943.2K | 81.15% | ↗ |
| 49 | 2018 | Tami Martin, R.N., Esq. Senior Vice President, Regulatory | 307.7K | — | — | 278.3K | 98.6K | 40.4K | 725.0K | 38.39% | ↗ |
| 50 | 2018 | Tami Martin, R.N., Esq. Senior Vice President, Regulatory Affairs | 307.7K | — | — | 278.3K | 98.6K | 40.4K | 725.0K | 38.39% | ↗ |
| 51 | 2017 | Jack A. Khattar Chief Executive Officer, President & Secretary | 614.0K | — | — | 4.42M | 498.0K | 41.1K | 5.57M | 79.30% | ↗ |
| 52 | 2017 | Stefan K.F. Schwabe, M.D., Ph.D. Executive Vice President of Research and Development, Chief Medical Officer | 378.0K | — | — | 679.8K | 159.0K | 31.6K | 1.25M | 54.45% | ↗ |
| 53 | 2017 | Victor Vaughn Former Senior Vice President of Sales and Marketing | 330.6K | — | — | 679.8K | 145.0K | 59.6K | 1.22M | 55.95% | ↗ |
| 54 | 2017 | Victor Vaughn Senior Vice President of Sales and Marketing | 330.6K | — | — | 679.8K | 145.0K | 59.6K | 1.22M | 55.95% | ↗ |
| 55 | 2017 | Gregory S. Patrick Senior Vice President, Chief Financial Officer | 351.0K | — | — | 679.8K | 143.0K | 21.3K | 1.20M | 56.88% | ↗ |
| 56 | 2017 | Gregory S. Patrick Vice President, Chief Financial Officer | 350.6K | — | — | 679.8K | 143.0K | 21.3K | 1.19M | 56.90% | ↗ |
| 57 | 2017 | Padmanabh P. Bhatt, Ph.D. Senior Vice President, Intellectual Property, Chief Scientific Officer | 358.0K | — | — | 543.8K | 137.0K | 24.5K | 1.06M | 51.15% | ↗ |
| 58 | 2017 | Padmanabh P. Bhatt, Ph.D Senior Vice President, Intellectual Property, Chief Scientific Officer | 357.6K | — | — | 543.8K | 137.0K | 24.5K | 1.06M | 51.17% | ↗ |
| 59 | 2017 | Tami Martin, R.N., Esq. Senior Vice President, Regulatory Affairs | 298.7K | — | — | 244.7K | 84.4K | 43.1K | 671.0K | 36.47% | ↗ |
| 60 | 2016 | Jack A. Khattar Chief Executive Officer, President & Secretary | 593.0K | — | — | 1.80M | 500.0K | 40.5K | 2.94M | 61.40% | ↗ |
| 61 | 2016 | Stefan K.F. Schwabe, M.D., Ph.D. Executive Vice President of Research and Development, Chief Medical Officer | 366.6K | — | — | 353.5K | 159.0K | 44.0K | 923.2K | 38.30% | ↗ |
| 62 | 2016 | Victor Vaughn Senior Vice President of Sales and Marketing | 319.8K | — | — | 353.5K | 144.0K | 59.4K | 876.8K | 40.32% | ↗ |
| 63 | 2016 | Victor Vaughn Former Senior Vice President of Sales and Marketing | 319.8K | — | — | 353.5K | 144.0K | 59.4K | 876.8K | 40.32% | ↗ |
| 64 | 2016 | Gregory S. Patrick Vice President, Chief Financial Officer | 340.6K | — | — | 353.5K | 147.0K | 23.2K | 864.4K | 40.90% | ↗ |
| 65 | 2016 | Gregory S. Patrick Senior Vice President, Chief Financial Officer | 340.6K | — | — | 353.5K | 147.0K | 23.2K | 864.4K | 40.90% | ↗ |
| 66 | 2016 | Padmanabh P. Bhatt, Ph.D Senior Vice President, Intellectual Property, Chief Scientific Officer | 347.6K | — | — | 282.8K | 131.0K | 24.2K | 785.6K | 36.00% | ↗ |
| 67 | 2016 | Padmanabh P. Bhatt, Ph.D. Senior Vice President, Intellectual Property, Chief Scientific Officer | 347.6K | — | — | 282.8K | 131.0K | 24.2K | 785.6K | 36.00% | ↗ |
| 68 | 2015 | Jack A. Khattar Chief Executive Officer, President & Secretary | 523.4K | — | — | 1.31M | 362.0K | 35.1K | 2.23M | 58.68% | ↗ |
| 69 | 2015 | Stefan K.F. Schwabe, M.D., Ph.D. Executive Vice President of Research and Development, Chief Medical Officer | 356.4K | — | — | 261.4K | 151.0K | 31.8K | 800.6K | 32.65% | ↗ |
| 70 | 2015 | Gregory S. Patrick Vice President, Chief Financial Officer | 330.5K | — | — | 261.4K | 141.0K | 19.5K | 752.4K | 34.75% | ↗ |
| 71 | 2015 | Padmanabh P. Bhatt, Ph.D. Senior Vice President, Intellectual Property, Chief Scientific Officer | 337.4K | — | — | 273.9K | 110.0K | 22.0K | 743.3K | 36.85% | ↗ |
| 72 | 2015 | Victor Vaughn Senior Vice President of Sales and Marketing | 291.6K | — | — | 183.0K | 110.0K | 46.5K | 631.2K | 29.00% | ↗ |
| 73 | 2015 | Padmanabh P. Bhatt, Ph.D Senior Vice President, Intellectual Property, Chief Scientific Officer | 337.4K | — | — | 156.9K | 110.0K | 22.0K | 626.3K | 25.05% | ↗ |
| 74 | 2014 | Jack A. Khattar Chief Executive Officer, President Secretary | 485.7K | — | — | 858.5K | 292.0K | 14.9K | 1.65M | 52.00% | ↗ |
| 75 | 2014 | Jack A. Khattar Chief Executive Officer, President & Secretary | 485.7K | — | — | 858.5K | 292.0K | 14.9K | 1.65M | 52.00% | ↗ |
| 76 | 2014 | Stefan K.F. Schwabe, M.D., Ph.D. Executive Vice President of Research and Development, Chief Medical Officer | 342.4K | — | — | 221.5K | 143.0K | 35.0K | 741.9K | 29.86% | ↗ |
| 77 | 2014 | Stefan K.F. Schwabe, M.D., Ph.D. Executive Vice President of | 342.4K | — | — | 221.5K | 143.0K | 35.0K | 741.9K | 29.86% | ↗ |
| 78 | 2014 | Gregory S. Patrick Vice President, Chief | 317.9K | — | — | 276.9K | 118.0K | 15.8K | 728.6K | 38.00% | ↗ |
| 79 | 2014 | Gregory S. Patrick Vice President, Chief Financial Officer | 317.9K | — | — | 276.9K | 118.0K | 15.8K | 728.6K | 38.00% | ↗ |
| 80 | 2014 | Padmanabh P. Bhatt, Ph.D. Senior Vice President, Intellectual Property, Chief Scientific Officer | 324.2K | — | — | 166.1K | 101.0K | 12.9K | 604.3K | 27.49% | ↗ |
| 81 | 2014 | Padmanabh P. Bhatt, Ph.D Senior Vice President, Intellectual Property, Chief Scientific Officer | 324.2K | — | — | 166.1K | 101.0K | 12.9K | 604.3K | 27.49% | ↗ |
| 82 | 2014 | Victor Vaughn Senior Vice President of Sales and Marketing | 282.9K | — | — | 166.1K | 88.0K | 32.9K | 570.0K | 29.15% | ↗ |
| 83 | 2013 | Jack A. Khattar Chief Executive Officer, President & Secretary | 462.9K | — | — | 1.88M | 231.8K | 15.3K | 2.59M | 72.57% | ↗ |
| 84 | 2013 | Jack A. Khattar Chief Executive Officer, President Secretary | 462.9K | — | — | 1.88M | 231.8K | 15.3K | 2.59M | 72.57% | ↗ |
| 85 | 2013 | Padmanabh P. Bhatt, Ph.D Senior Vice President, Intellectual Property, Chief Scientific Officer | 314.8K | — | — | 383.3K | 90.8K | 14.8K | 803.7K | 47.70% | ↗ |
| 86 | 2013 | Padmanabh Bhatt, Ph.D. Senior Vice President, Intellectual Property, Chief Scientific Officer | 314.8K | — | — | 383.3K | 90.8K | 14.8K | 803.7K | 47.70% | ↗ |
| 87 | 2013 | Gregory S. Patrick Vice President, Chief | 308.9K | — | — | 335.4K | 109.0K | 15.9K | 769.3K | 43.60% | ↗ |
| 88 | 2013 | Gregory S. Patrick Vice President, Chief Financial Officer | 308.9K | — | — | 335.4K | 109.0K | 15.9K | 769.3K | 43.60% | ↗ |
| 89 | 2013 | Gregory S. Patrick Vice President, Chief Financial Officer | 308.9K | — | — | 335.4K | 109.0K | 15.9K | 769.3K | 43.60% | ↗ |
| 90 | 2013 | Victor Vaughn Senior Vice President of Sales and Marketing | 253.1K | — | — | 407.3K | 74.3K | 23.5K | 758.2K | 53.72% | ↗ |
| 91 | 2013 | Stefan K.F. Schwabe, M.D., Ph.D. Executive Vice President of | 332.8K | — | — | 95.8K | 111.8K | 37.3K | 577.8K | 16.59% | ↗ |
| 92 | 2013 | Stefan K.F. Schwabe, M.D., Ph.D. Executive Vice President of Research and Development, Chief Medical Officer | 332.8K | — | — | 95.8K | 111.8K | 37.3K | 577.8K | 16.59% | ↗ |
| 93 | 2012 | Stefan K.F. Schwabe, M.D., Ph.D Executive VP of RD, | 156.2K | — | — | 786.8K | 58.3K | 30.0K | 1.03M | 76.30% | ↗ |
| 94 | 2012 | Jack A. Khattar Chief Executive Officer, President Secretary | 438.5K | — | — | — | 247.8K | 11.2K | 697.5K | 0.00% | ↗ |
| 95 | 2012 | Jack A. Khattar Chief Executive Officer, President | 438.5K | — | — | — | 247.8K | 11.2K | 697.5K | 0.00% | ↗ |
| 96 | 2012 | Padmanabh Bhatt, Ph.D. Senior Vice President, Intellectual | 295.9K | — | — | — | 96.4K | 13.7K | 406.0K | 0.00% | ↗ |
| 97 | 2012 | Padmanabh Bhatt, Ph.D. Senior Vice President, Intellectual Property, Chief Scientific Officer | 295.9K | — | — | — | 96.4K | 13.7K | 406.0K | 0.00% | ↗ |
| 98 | 2012 | Gregory S. Patrick Vice President, Chief Financial Officer | 276.7K | — | — | — | 102.5K | 13.6K | 392.7K | 0.00% | ↗ |
| 99 | 2011 | Jack A. Khattar Chief Executive Officer, President | 420.2K | — | — | — | 168.1K | 11.4K | 599.7K | 0.00% | ↗ |
| 100 | 2011 | Padmanabh Bhatt, Ph.D. Senior Vice President, Intellectual | 274.2K | — | — | — | 67.2K | 12.7K | 354.0K | 0.00% | ↗ |
| 101 | 2011 | Stefan K.F. Schwabe, M.D., Ph.D Executive VP of RD, | — | — | — | — | — | — | — | — | ↗ |
CEO compensation breakdown
Proxy statements
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jack A. Khattar | Founder, President, Chief Executive Officer, Secretary & Director | 2M | male |
| Timothy C. Dec | Senior Vice President & Chief Financial Officer | 772.1K | male |
| Jonathan Rubin | Senior Vice President of Research & Development and Chief Medical Officer | 710.3K | — |
| Padmanabh Bhatt | Chief Scientific Officer & Senior Vice President of Intellectual Property | 657.9K | — |
| Frank Mottola | Senior Vice President & Chief Technology Operations Officer | 571.6K | male |
| Bryan A. Roecklein | Senior VP & Chief Business Officer | — | — |
| William Todd Horich | Senior VP & Chief Commercial Officer | — | — |
| Jeff Bozick | Senior Vice President of Supply Chain | — | male |
| Kevin T. Anderson | Compliance Officer | — | male |
| Taylor Raiford | Senior Vice President of Sales | — | male |
| Todd Horich | Senior VP & Chief Commercial Officer | — | — |
ESG Rating
ESG Score History DRUG MANUFACTURERS - SPECIALTY & GENERIC
Benchmark vs Sector
Political Trading Activity (25M)
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
| Transaction Date | Disclosed | Representative | District | Owner | Type | Amount | Link |
|---|---|---|---|---|---|---|---|
| 2025-12-11 | 2026-01-12 | Gilbert Cisneros | CA31 | — | Purchase | $1,001 - $15,000 | ↗ |
| 2025-10-09 | 2025-11-18 | Gilbert Cisneros | CA31 | — | Sale (Partial) | $1,001 - $15,000 | ↗ |
| 2025-03-24 | 2025-04-07 | Gilbert Cisneros | CA31 | — | Purchase | $1,001 - $15,000 | ↗ |
| 2022-12-23 | 2023-01-13 | Josh Gottheimer | NJ05 | Joint | Sale (Partial) | $1,001 - $15,000 | ↗ |
| 2020-11-13 | 2020-12-15 | Gilbert Cisneros | CA31 | — | Purchase | $1,001 - $15,000 | ↗ |
| 2020-07-17 | 2020-08-19 | Gilbert Cisneros | CA31 | — | Purchase | $1,001 - $15,000 | ↗ |
| 2020-06-01 | 2020-06-16 | Gilbert Cisneros | CA31 | — | Purchase | $1,001 - $15,000 | ↗ |
| 2020-05-28 | 2020-06-10 | Josh Gottheimer | NJ05 | Joint | Purchase | $1,001 - $15,000 | ↗ |
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for SUPN
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
